Who
John F. Paolini
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Kiniksa Pharmaceuticals International.
In numbers
- Trades disclosed
- 219
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $19.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Sep 2018
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,497 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,624 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,497 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,624 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,750 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —6,700 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —26,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,457 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,624 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,497 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,457 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code F | $319K4,029 at $79.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —6,700 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —26,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,457 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,497 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,624 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —1,750 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name John F. Paolini; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.